RPAM
ONC

Rhenman & Partners Asset Management’s BeOne Medicines Ltd ONC Stock Holding History

Rhenman & Partners Asset Management’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-20,000
Closed -$2.46M – 97
2020
Q1 		$2.46M Hold
20,000
– – 0.34% 72
2019
Q4 		$3.31M Buy
+20,000
New +$3.32M 0.36% 74

Other funds holding ONC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
CII
Capital International Inc Los Angeles, California $13B AUM 31.88% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Rhenman & Partners Asset Management's ONC Position: Q2 2020 in Review

Rhenman & Partners Asset Management sold out of BeOne Medicines Ltd (ONC) in Q2 2020, closing a stake of 20,000 shares — an estimated $2.46M sold.

Rhenman & Partners Asset Management first reported a position in ONC in Q4 2019 and held it in 2 quarters. The position peaked at $3.31M in Q4 2019. 220 funds tracked by Wall St. Rank hold ONC as of Q2 2020.

  • Rhenman & Partners Asset Management reported no remaining BeOne Medicines Ltd position as of Q2 2020 after selling out during the quarter.
  • Rhenman & Partners Asset Management sold 20,000 BeOne Medicines Ltd shares in Q2 2020, an estimated $2.46M.
  • Rhenman & Partners Asset Management first reported a position in BeOne Medicines Ltd in Q4 2019 and held it in 2 quarters.
  • Rhenman & Partners Asset Management's BeOne Medicines Ltd position peaked at $3.31M in Q4 2019.
  • 220 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2020.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2020, filed 16 Jul 2020.